Baseline data from the control arm of the STAMPEDE trial

One of the more interesting sets of data on metastatic prostate cancer to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago this year will be some of the very earliest data from the STAMPEDE trial, which we have discussed in some detail in an earlier post. … READ MORE …

Clinical “success” and the management of low-risk, localized prostate cancer

Historically, “success” in the treatment of localized prostate cancer was the elimination of all evidence of cancer from the patient’s prostate and other nearby tissues — through radical surgery or radiation therapy of some type. But the increasing acceptance of active surveillance and the evolution of focal forms of therapy have introduced whole new ways of thinking about the “successful” management of low- and even intermediate-risk, localized disease. … READ MORE …


Get every new post delivered to your Inbox.

Join 1,454 other followers